One POP May Fit MORE Women Like You! Slynd®, for pregnancy prevention, is the first and only progestin-only pill (POP) with a 24-hour intake window and 24 active + 4 inactive pill dosing regimen.

*Slynd® can be used in many patient types. It is at the provider’s discretion to determine appropriateness for individual patients. Please see Slynd® Prescribing information for more details.

Already a Slynd user? Tell us about your experiences

Slynd® may be fit for more women like you…

“I’m breastfeeding, so my only option is a pill with a tight dosing schedule that wreaks havoc on my periods.”

“I like to have fun and look my best. I want to balance my hormones to keep my skin clear but not take any extra hormones beyond what is absolutely necessary.”

“Some oral contraceptives don’t work on women with my body type.”

“I smoke so my contraceptive shouldn’t contain estrogen. My pill has a dosing schedule that stresses me out.”

Slynd® is the only POP with a 24-hour dosing window…

The goal is to never miss a dose of your oral contraceptive, but if you do, Slynd® can be more forgiving than other progestin-only pills in terms of what you have to do to get back on track with your regular schedule, while ensuring continued birth control protection.

24 white (active) pills 

each containing 4 mg of drospirenone for Week 1 through Week 3 and the first 3 days

of Week 4 (Days 1-24)

4 green (placebo) pills

for the last 4 days of Week 4 (Days 25-28)

24 white (active) pills 

each containing 4 mg of drospirenone for Week 1 through Week 3 and the first 3 days of Week 4 (Days 1-24)

4 green (placebo) pills

for the last 4 days of Week 4 (Days 25-28)

And Slynd® has a 24+4 dosing regimen

Slynd® has a monthly dosing schedule that will be familiar to you if you’ve ever used an estrogen-containing oral contraceptive. The Slynd® 24+4 dosing regimen can help you manage your periods and bleeding days to fit your lifestyle and expectations better. 

Slynd® is safe and effective


Evaluated in over 20,000 cycles

What doctors are saying about Slynd®

“Slynd® has changed the way I think about contraceptives. With Slynd®, my patients can now benefit from the safety of a progesterone-only pill while experiencing excellent cycle control.”


Jason W. Pollock, MD, FACOG

Murfreesboro Medical Clinic
Murfreesboro, Tennessee

“Birth control is a personal decision. The pill is the mainstay that women have used for generations, but increasingly women are refusing estrogen-containing options but want the reliability and safety that the pill offers. This pill is what my patients are looking for.”


Julianne Adams Birt, MD, FACOG

President ~ Radiant Women’s Health
Conyers, Georgia

“Slynd® is a welcomed addition to our war chest for contraceptive health not only for breastfeeding women, those with CV risk patients, obese women and for the younger teens but also a safe and effective option for the every woman.”


Michael Krychman, MD

Southern California Center for Sexual Health and Survivorship Medicine
Newport Beach, California

“The FDA approval of Slynd® is a significant milestone for women in the United States because it is effective in normal and overweight women, and does not increase the risk of venous blood clots.”


David F. Archer, MD

Professor of Obstetrics and Gynecology Eastern Virginia Medical School
Norfolk, Virginia

“The introduction of Slynd® to the U.S. market is exciting as the need for a new form of progestin-only oral contraception is long overdue. Slynd® provides women and couples a contemporary and modern option to plan their families. It is effective, has good menstrual cycle regulation, and is a safe option for many women who otherwise cannot use estrogen-containing forms of birth control.”


Thomas D. Kimble, MD

Eastern Virginia Medical School
Norfolk, Virginia

References (click to expand)

1. Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Acc J Contracept. 2016;7:43-52. doi: 10.2147/OAJC.S85565
2. Slynd [package insert]. Exeltis USA, Inc.; Florham Park, NJ; 2019.
3. Data on file. Exeltis USA, Inc.; Florham Park, NJ; 2019.
4. Fuhrmann U, Krattenmacher R, Slater ED, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996;54(4):243-251
5. Regidor PA, Schindler AE. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestins: dienogest and drospirenone. Oncotarget. 2017:8 (47): 83334-83342.
6. Vroonen L, Cavalier E, Vranken L, et al. Influence of drospirenone on renin-angiotensin-aldosterone system evaluation. Endocrine Abstracts. 2011;26:12.
7. Slopien R, Milewska E, Rynio P, et al. Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age. Menopause Review. 2018;17(1):1-4. doi: 10.5114/pm.2018.74895
8. Greer JB, Modugno F, Allen G, et al. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet Gynecol. 2005;105:731-740.
9. Batur P. Female contraception. Cleveland Clinic Center for Continuing Education. Published December 2016.
10. Glisic M, Shahzad S, Tsoli S, et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis Eur J Prev Cardiol. 2018;25(10):1042-1052. doi: 10.1177/2047487318774847.
11. Duijkers IJM, Heger-Mahn D, Drouin D, et al. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception. 2016:93(4): 303-309.


    Please confirm the following information:

    Your Name*

    Practice Location*

    Your NPN*